Phase 2 N=12 An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
GNE Myopathy
Primary: Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted) — 7461; 9432 hr*ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 LEO 124249 Ointment in the Treatment of Alopecia Areata
Alopecia Areata
Primary: Change in Severity of Alopecia Areata Tool (SALT) Score — -3.8; -3.4 units on a scale — p=0.97
Phase 2 N=20 Vitamin C in Atrial Fibrillation Ablation
Atrial Fibrillation Ablation
Primary: Change in Creatinine Levels — -0.1; -0.1 mg/dL
Phase 2 N=154 A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) — 9.2; 7.8 months — p=0.09
Phase 2 N=106 Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression Free Survival — 6.2; 7.5 months
Phase 2 N=30 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: 6-month Progression-free Survival — 90 months
Phase 2 N=60 Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Prostate Cancer
Primary: Safety, Feasibility and Tolerance of Revlimid as Assessed by Number of Participants Experiencing Grade 3 and 4 Adverse Events. — 3; 10 Participants
Phase 2 N=92 Pioglitazone for Lung Cancer Chemoprevention
Lung Cancer · Endobronchial Dysplasia
Primary: 6-month Histology Score — 3.07; 3.71 Units on a scale — p=0.53
Phase 2 N=260 Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Chronic Phase Chronic Myeloid Leukemia
Primary: Percentage of Patients Achieving Major Molecular Response (MMR) After 12 Months of CML Treatment — 12.8; 28.7 Percentage of Patients — p=0.005
Phase 2 N=40 Dipyridamole for Immune Activation in HIV
HIV Infection
Primary: Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 — 244500.00; -58250.00 pg/ml — p=0.8220
Phase 2 N=40 Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery
Postoperative Ocular Pain After PRK Surgery
Primary: Visual Analog Scale (VAS) Pre-dose Pain Assessment — 34.63; 45.76 score on a scale — p=0.005
Phase 2 N=60 Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Influenza
Primary: Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] — 10; 10; 10; 15 Participants
Phase 2 N=37 Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Physical Activity
Primary: Change From Baseline of Maximal Oxygen Uptake at Week 12 — 26.9; 30.1; 30.6; 32.4 Milliliters/Kilogram/Minute
Phase 2 N=214 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
Asthma
Primary: Time to First Asthma Worsening During the Planned 24 Week Treatment Period — 40.00; 85.50 Days — p=0.0255
Phase 2 N=60 Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
Respiratory Distress Syndrome, Adult
Primary: Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion — 0; 0 Participants